Fishers-based gene therapy firm plans $40M expansion, 62 new jobs

Fishers-based cell and gene therapy contract development and manufacturing organization Genezen Laboratories Inc. said Tuesday it will invest $40 million to expand its Fishers facility and create up to 62 jobs by the end of 2023.

The company said the 75,000-square-foot addition will triple its current footprint.

Genezen said the investment will allow it to upgrade its cGMP lentiviral and retroviral vector production at the facility in the Crosspoint Business Park. The facility is at 9900 Westpoint Drive, west of Interstate 69 and north of 96th Street. Viral vectors are commonly used in gene therapy to deliver genetic materials into human cells.

“This is an exciting stage of Genezen’s growth journey as we continue to grow and prosper within the Indiana community,” Ray Kaczmarek, chief executive officer at Genezen, said in a written statement. “The talent and biotech expertise in Indiana is flourishing, and we are highly confident that we’ll continue to build a world-class team supporting our clients as they bring life-changing therapies to market.”

Work is underway and Genezen said it expects the new manufacturing suites to be operational in the first half of 2022. The company is actively hiring in a variety of areas, including business development, finance, human resources, vector manufacturing, and quality.

Genezen originally operated out of Launch Fishers and announced plans in April 2020 to invest nearly $8 million to establish its space at the business park and create 36 jobs, a number expected to be exceeded by the end of this year.

Fishers Mayor Scott Fadness said in a press release that Genezen’s announcement builds on the city’s focus on life science innovation and entrepreneurship.

The Indiana Economic Development Corp. has offered Genezen up to $1 million in conditional tax credits and training grants, which the company will not be able to claim until Hoosier workers are hired. The Fishers City Council has approved additional incentives.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our updated comment policy that will govern how comments are moderated.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets in {{ count_down }} days.